Accelrys To Provide Technology For Functional Annotation of Confirmant's Protein Atlas of the Human Genome(TM)
Tuesday February 11, 12:01 am ET
SAN DIEGO and ABINGDON, England, Feb. 11 /PRNewswire-FirstCall/ -- Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP - News), and Confirmant Ltd., a provider of innovative bio-information, today announced a technology software alliance that will result in a novel database consisting of highly annotated proteins which could provide the pharmaceutical industry with crucial data for prioritizing the selection of drug targets and accelerating drug discovery.
Under the terms of the agreement, Confirmant will license Accelrys' GeneAtlas(TM) software product, an application for high throughput sequence and structure-based functional annotation. Confirmant will use GeneAtlas(TM) to annotate the function of protein sequences contained within The Protein Atlas of the Human Genome(TM), Confirmant's comprehensive database of proteins that can be directly mapped back to the human genome.
These annotations will be commercially available from Confirmant within Accelrys' Discovery Studio AtlasStore(TM) database (DS AtlasStore) an Oracle-based enterprise-wide database that integrates protein sequence, structure and annotation data. This new database will be marketed by both parties as a complementary and valuable addition to the Protein Atlas.
"Through their unique approach, Confirmant has made significant progress in uncovering the potential of genomics and genetics for drug discovery," said Dr. Scott Kahn, chief science officer, Accelrys. "By linking the experimental proteomic data in Confirmant's Protein Atlas with the annotations in DS AtlasStore, Accelrys and Confirmant will be able to provide the drug discovery industry with a new level of information for disease-related-proteins."
"We are pleased to be working with Accelrys to supply scientists with an unambiguous protein-centric view of the human genome," said David Palmer, CEO of Confirmant. "We believe the combination of our extensive proteomic data with Accelrys' annotation tools will be extremely powerful in helping scientists develop new therapeutic and diagnostic products."
About Confirmant
Confirmant Ltd. provides novel and unique post-genomic bio-information to the pharmaceutical, biotechnology and medical research communities. Based on experimentally derived human protein sequence determination, Confirmant's first database product, The Protein Atlas of the Human Genome(TM), is the first definitive database of human proteins and already includes some 11,000 protein-coding genes and their fine structure as well as the protein variants they encode. This information will more reliably aid in the identification and validation of drug targets and disease biomarkers, resulting in faster and more effective development of new treatments and diagnostics. Confirmant is a joint venture between Oxford GlycoSciences (LSE: OGS - News; Nasdaq: OGSI - News) and Marconi (MONI) and is based in Abingdon in the United Kingdom. For more information, go to confirmant.com.
About Accelrys Inc.
Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise-wide solutions tailored to today's leading research organizations. The company's two main centers of excellence are in San Diego, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP - News).
More information on Accelrys can be found at accelrys.com .
Discovery Studio, AtlasStore and GeneAtlas are registered trademarks of Accelrys Inc. within the United States and/or various other countries.
When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Jim Rivas
Accelrys
1-858-799-5393
jrivas@accelrys.com
Geraldine Floresca
Neale-May & Partners
1-650-328-5555 x501
gfloresca@nealemay.com |
